Celltrion and Dongbang FTL will develop and manufacture generic drugs under the license contract and supply them to 95 low- and middle-income countries.
South Korea will supply generic drugs for Covid-19 therapy to low- and middle-income countries with two pharmaceutical companies, Celltrion and Dongbanf FTL, which have obtained the license to manufacture them. Celltrion and Dongbang FTL will develop and manufacture generic drugs under the license contract and supply them to 95 low- and middle-income countries. Celltrion plans to complete the development and commercialization of the drug, after which the finished drug will be manufactured at Cheongju Pharmaceutical factory.
Celltrion recently signed a contract with the UN Medicine Patent Pool (MPP) for the generic production of Pfizer’s oral Covid-19 treatment.
This comes close on the heels of Pfizer’s decision to expand the accessibility of its Covid-19 drug in low- and middle-income countries through MPP. The license was only granted to 35 companies in 12 countries.
Korean companies Dongbang, Celltrion and Hanmi Pharmaceutical FTL can manufacture and supply generic drugs after obtaining a license for the oral Covid-19 treatment of MSD.
Starting with the production of the AstraZeneca vaccine and also the Novavax vaccine, SK Bioscience has become the hub of Asian vaccine production.
Samsung Biologics currently manufactures and supplies Moderna’s Covid-19 vaccines and also produces antibody Covid-19 treatments from Lilly, GSK and AstraZeneca. Hanmi Pharmaceutical, developed by Zydus Cadila of India, will also produce a plasmid DNA COVID-19 vaccine ‘Zycov-D’ on consignment.
This post South Korean pharmaceutical companies to supply generic Covid-19 drugs to low- and middle-income countries was original published at “https://www.financialexpress.com/healthcare/south-korean-pharmaceutical-companies-to-supply-covid-19-generic-drugs-to-low-and-middle-income-countries/2466690/”
